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Computed Tomography for
Diagnosis of Prosthetic
Valve Endocarditis
Saby et al. (1) should be commended for their recent attempt
to address limitations of modiﬁed Duke Criteria to diagnose
infective endocarditis in patients with prosthetic valve (PVE).
These investigators suggested that abnormal ﬂuorodeoxyglucose
(FDG) uptake on 18F-FDG positron emission tomographic/
computed tomographic (PET/CT) scanning should be included
as a novel major criterion for PVE due to its high sensitivity and
speciﬁcity (1).
However, it should be noted that the false-positive rate may be
underestimated in this study because testing was performed in
patients with high pre-test probability. Abnormal FDG uptake is
not speciﬁc for infectious processes and can be found in various
other common conditions, such as soft atherosclerotic plaques,
vasculitis, thrombi, or malignancy (2,3). Also, cardiac FDG uptake
rates are lower in patients with heart failure and in patients who are
taking drugs such as metformin, ﬁbrate, and synthyroid (4,5).
Further, PVE due to organisms that can form bioﬁlms (e.g.,
Escherichia coli and Candida albicans) might result in high rate of
false-negative tests.
A 18F-FDGPET scan is based on increased uptake of 18F-FDG
by inﬂammatory cells, and it may miss the initial process of leukocyte
migration due to the short half-life of 18F FDG (w110 min).
Diagnostic accuracy of an 18F-FDG PET/CT scan early in thecourse of disease was still not clear in current study (1) because the
scan was performed a median of 9 days after initiation of treatment.
Lower diagnostic accuracy of the modiﬁed Duke Criteria warrant
inclusion of a better diagnostic study that has high sensitivity and
speciﬁcity to localize infectious processes. However, whether revised
criteria to diagnose PVE should include 18F-FDG PET/CT
scanning, single-photon emission computed tomography/CT with
radiolabeled leukocytes scintigraphy (which is reported to have high
diagnostic accuracy to diagnose PVE even in early post-operative
cases), or both, is still not clear and needs to be addressed in
future studies.*Abhishek Sharma, MD
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We thank Dr. Sharma for his comments with regard to our recently
published report (1). As demonstrated by this study and then pointed
out by the author of the present letter, Positron emission tomog-
raphy/computed tomography (PET/CT) does not have 100%
speciﬁcity for the diagnosis of prosthetic valve endocarditis (PVE).
Obviously, the diagnostic value of this technique depends on the pre-
test probability, and thus depends on the medical history of the
patients, as well as their clinical, microbiological, and imaging data.
Therefore, the take-home message of our work is not to consider
PET/CT as a technique able to diagnose PVE without other data. It
should be used with the global assessment of the patients with sus-
pected PVE. That is why we recommend considering the results of
this technique in the new 2013 modiﬁed Duke classiﬁcation.
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862Metformin, ﬁbrate, and levothyroxin could reduce the myo-
cardial 18ﬂuoro-2-deoxyglucose (FDG) uptake as previously
demonstrated (2). However, this phenomenon could better visu-
alize abnormal uptake of the valvular and perivalvular tissues. The
reduction of this physiological myocardial FDG uptake is of crucial
importance for a better interpretation of images of valvular and
perivalvular sites. To achieve this goal, we recommend that patients
eat a meal rich in fat and very low in carbohydrates the day before
and then fast for at least 12 hours before PET/CT.
Sharma hypothesizes that bioﬁlm might reduce FDG uptake;
however, this has never been demonstrated by any study. In our
study, we did not observe a signiﬁcant difference in terms of FDG
uptake according to the causative pathogen (p ¼ 0.52). Moreover,
some studies showed that abnormal FDG uptake in a pacemaker
and/or deﬁbrillator leads to endocarditis, a disease in which bioﬁlm
formation is strongly involved (3).
Inﬂammatory cells, especially monocytes, are strongly involved
in the pathogenesis of infective endocarditis. They are present
early in the valvular site. Then, their number and their activity
rapidly increase after the adhesion and the invasion by the
pathogen (4). Thus, the clinical manifestations that lead to
a suspicion of PVE usually occur when the metabolic activity of
the inﬂammatory cells in the valvular site is already high, allowing
its visualization by PET/CT. In our study, PET/CT was per-
formed at a median time of 6 days after admission, which is
relatively early given the usual availability of this type of imaging
modality. To reduce the diagnostic process, we hope to decrease
this delay in the future.*Franck Thuny, MD, PhD
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